SIGA Reports Financial Results for Three and Nine Months Ended September 30, 2022

About this update from Siga Technologies Inc.

- Approximately $61 Million of International Sales in the Third Quarter – - Corporate Update Conference Call Today at 4:30 PM ET NEW YORK, Nov. 03, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three and nine months ended September 30, 2022. “With significant international sales, our third quarter financial results continue a trend of substantial financial diversification at SIGA,” said Phil Gomez, CEO of SIGA. “In combination with the first sale of the intravenous formulation of TPOXX® (“IV TPOXX”) in the first quarter of 2022 and the first sale of oral TPOXX to the U.S. Department of Defense (“DoD”) in the second quarter of 2022, the sale of oral TPOXX (tecovirimat) to ten new international customers in the third quarter of 2022 highlights the continuing diversification of SIGA’s revenue base. We believe the expanded number of customers is a sign that more leaders in government are recognizing the critical importance of health security preparedness, and that by increasing both the scale and scope of TPOXX stockpiling, countries can be better prepared to address the risks associated with smallpox, monkeypox, and other viruses in the orthopoxvirus family of viruses.” Summary Financial Results($ in millions, except per share amounts) Third Quarter 2022 in comparison to Third Quarter 2021 Three Months EndedSeptember 30, 2022 Three Months Ended September 30, 2021Total RevenuesOperating Income (Loss) (1)Income (Loss) before Income Taxes (1)Net Income (Loss) Diluted Income (Loss) per Share$72.2$42.9$43.1$33.0$ 0.45 per share $4.8($2.9)($4.0)($3.1)($0.04) per share Nine Months Ended September 30, 2022 in comparison to Nine Months Ended September 30, 2021 Nine Months EndedSeptember 30, 2022 Nine Months Ended September 30, 2021Total RevenuesOperating Income (Loss) (1)Income (Loss) before Income Taxes (1)Net Income (Loss) Diluted Income (Loss) per Share$99.4$44.5$45.3$34.7$ 0.47 per share $18.3($4.9)($4.6)($3.8)($0.05) per share (1) Operating Income / (Loss) excludes, and Income / (Loss) before Income Taxes includes, interest income, and adjustments to the fair value of the Company’s outstanding warrant. Both line items exclude the impact of income taxes. Key Business and Operational Activity This year, through October 31, SIGA has received approximately $...

View stock analysis, news, and events for Siga Technologies Inc.